Document is current
Any future updates will be listed below
-
Authors
Riwes, Mary M. https://orcid.org/0000-0001-5764-0410
Golob, Jonathan L.
Magenau, John
Shan, Mengrou
Dick, Gregory
Braun, Thomas
Schmidt, Thomas M.
Pawarode, Attaphol
Anand, Sarah
Ghosh, Monalisa
Maciejewski, John
King, Darren
Choi, Sung https://orcid.org/0000-0002-6321-3834
Yanik, Gregory
Geer, Marcus
Hillman, Ethan
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Tewari, Muneesh
Reddy, Pavan https://orcid.org/0000-0001-7264-8429
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01 HL149633, P01 HL149633, P01 HL149633)
- License Information
-
More Information
Article History
Received: 30 March 2023
Accepted: 12 September 2023
First Online: 19 October 2023
Competing interests
: J. Magenau received consulting fees from INHIBR<sub>X</sub>. M.G. received consulting fees from Cabaletta Bio. C.A.L. received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics and T-knife Therapeutics, and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer and targeting the GOT1 pathway as a therapeutic approach (US patent no. 2015126580-A1, 7 May 2015; US patent no. 20190136238, 9 May 2019; international patent no. WO2013177426-A2, 23 April 2015). All other authors declare no competing interests.
